Name: PeptIQ Claim Audit — darkperformancesystems
Rating: 5
Author: PeptIQ

Audited March 3, 2026 · by PeptIQ

✅Supported

The scientific literature provides strong evidence supporting retatrutide's multi-receptor mechanism. A comprehensive Phase 2 human trial demonstrated the peptide's ability to simultaneously engage GLP-1, GIP, and glucagon receptors, with meaningful clinical outcomes in type 2 diabetes management.

Post captionshow

R*trutide's Phase 3 data reveals a unique mechanism for weight loss, distinct from other drugs. Understanding its action is key to unlocking its potential.

Video transcriptshow

Retatrutide's phase three trial results just dropped. After actually reading the data myself, I'm not surprised at all. Because for the last 10 weeks, I've been personally experimenting with RETA and I can tell you right now, this is not just a fat loss drug. This is not Ozempic with better marketing. This is definitely not something you can understand through Instagram clips if you never used it …

Show full video transcript

before. As someone who spent years abusing fat burners and stimulants and steroids, Retatrutide is a completely different animal. So in this video, I'm gonna break down the phase three data and what actually it showed because there's parts of this that people are ignoring and why this drug actually behaves differently than semi-glutide and terzeptide. And then I'm gonna walk you through my personal 10-week protocol. I'm gonna talk to you about the dosing, the timing, how I stacked with the other peptides and how I got back down to roughly 8% body fat without wrecking my body and losing my muscle. Let's get into it. Retrutide is a tripital agonist compound, right? So it targets three things, GLP-1, GIP, glucagon. All these receptors are getting hit at the same time. That is a difference right there than your traditional GLP-1s that just suppress your appetite, stop you from eating, and of course you're going to lose weight.

Show less

Claim Breakdown(1 claim found)

“Retatrutide targets three receptors: GLP-1, GIP, and glucagon.”

✅Supported

A Phase 2 human clinical trial confirms retatrutide targets GLP-1, GIP, and glucagon receptors, with robust evidence of multi-receptor agonist activity in type 2 diabetes management.

Supporting studies

Share this audit

Preview post text

✅ AI fact-checked @darkperformancesystems's peptide claims:

Verdict: SUPPORTED
The scientific literature provides strong evidence supporting retatrutide's multi-receptor mechanism…
1 claim checked vs PubMed.

Full breakdown 👇
https://peptiq.io/check/51e28af2-ffbe-4cf8-b817-b6bfcfa6791c

@peptiq.io #PeptideScience #Biohacking

https://peptiq.io/check/51e28af2-ffbe-4cf8-b817-b6bfcfa6791c

Audit another post

3 free per day, no account needed

New audit

Track your peptide protocols

Download the PeptIQ app for dosing, logging, and more

Get the app

This audit is for educational purposes only. Not medical advice. Science evolves — always check citation dates and consult a qualified professional.

Report an error